PPARA and congestive heart failure: However, the development of several PPARα/γ agonists (e.g., naveglitazar, tesaglitazar, aleglitazar, ragaglitazar, peliglitazar, reglitazar, cevoglitazar, farglitazar, muraglitazar, imiglitazar, and sipoglitazar) and PPAR pan agonists (sodeglitazar and indeglitazar) have been discontinued in both preclinical and clinical studies, mainly because of cardiovascular adverse events, congestive heart failures, and the subsequent increased mortality perhaps caused by their full (potent) PPARγ activation [9].